QHSLab, Inc. (USAQ) stock
Close on Oct 19, 2026Market cap $7.38MP/E –Yield –
QHSLab, Inc. grew revenue 24.6% to $3.02M over the twelve months to Jun 30, 2026. Operating income fell 48.9% to $82.62K, moving the operating margin from 6.7% to 2.7%. At the latest close the market valued the company at $7.38M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $7.38M
- P/E ratio
- –
- Price to sales
- 2.45
- Price to book
- 4.74
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $3.02M
- Net income
- -$390.73K
- EPS, diluted
- -$0.03
- Book value per share
- $0.07
- Diluted shares
- 23M
Trading
- Previous close
- $0.32
- Open
- $0.32
- Day's range
- $0.32 – $0.32
- Volume
- 0
- Average volume (20 days)
- 4,244
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | USAQ | S&P 500 | Difference | USAQ per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -8.6% | +0.6% | −9.2 pts | ||
| 3 months | +0.9% | +3.4% | −2.4 pts | ||
| Year to date | -47.2% | +13.3% | −60.5 pts | ||
| 1 year | +46.8% | +16.6% | +30.2 pts | ||
| 3 years | +966.7% | +86.4% | +880.3 pts | +120.1% | +23.1% |
| 5 years | -55.6% | +81.9% | −137.4 pts | -15.0% | +12.7% |
| 10 years | +190.9% | +318.9% | −127.9 pts | +11.3% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Press releases
Releases QHSLab filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About QHSLab
Surgical & Medical Instruments & Apparatus
QHSLab, Inc. is a digital health company that enables independent, physician-led primary care practices to detect, document, and manage behavioral health conditions. Its workflow-integrated digital platform facilitates population-based screening, adaptive clinical risk assessments, automated documentation within electronic health records, and longitudinal non-face-to-face care management. Alongside its digital software, the company offers AllergiEnd, an allergy diagnostics and treatment line featuring disposable skin test applicators and customized immunotherapy support to evaluate and treat allergic conditions directly within clinical practices. Its primary target clientele consists of independent medical practices with one to ten healthcare providers.
Company profile, executives and historyQHSLab stock: common questions
What is QHSLab's stock price?
USAQ closed at $0.32 on Oct 19, 2026, up 0.00% on the day.
What is QHSLab's market cap?
QHSLab was worth $7.38M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is USAQ's P/E ratio?
QHSLab lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.03), so it has no meaningful P/E ratio.
How much revenue does QHSLab make?
QHSLab reported revenue of $3.02M for the twelve months to Jun 30, 2026, up 24.6% from a year earlier.
Does QHSLab pay a dividend?
No. QHSLab has not paid a cash dividend over the last twelve months.
How has USAQ stock performed over the past year?
Including dividends, USAQ returned +46.8% over the past year, against +16.6% for the S&P 500.
Who are QHSLab's competitors?
Companies most similar to QHSLab by business, industry and size include LUCD, AURX, INBS, VYCO, SINT.
See a number that looks wrong?